type your search, and then press enter

News & Events

See what’s new in the field of hereditary eye diseases

Blog managed by the DBGen team, with updated therapies, news and events involving hereditary eye diseases. We invite you to take part in this forum.

World Sight Day to raise awareness of blindness and visual impairment

09/10/19 - Patients,

World Sight Day is observed annually on the second Thursday of October. This global event coordinated by The International Agency for the Promotion of Blindness (IAPB) in cooperation with the World Health Organization (WHO) is meant to raise public awareness of blindness and vision impairment as major international public health issues. World Sight Day aims to influence governments/ministers of health...

read more

Gene therapies open very promising scenarios for the treatment of genetic blindness

Not so far ago, a patient that was clinically diagnosed with a retinal inherited dystrophy had to face an unavoidable outcome, eventual blindness. No effective treatment to cure or halt the progression of the disease was available. This gloomy perspective has been completely upturned by the implementation of cutting edge technologies, and the future looks promising for patients and their...

read more

New RNA therapy for autosomal dominant retinitis pigmentosa

The United States Food and Drug Administration (FDA) has just approved the designation of the QR-1123 therapy by the Dutch company ProQR as a new investigational drug. This drug aims to treat a form of autosomal dominant retinitis pigmentosa (RPad) caused by the P23H mutation in the rhodopsin gene (RHO). QR-1123 is an antisense oligonucleotide, that is, a short RNA...

read more

A race against the clock for Leber congenital amaurosis gene therapy

ProQR Sepofarsen therapy On July 29, the Dutch company ProQR announced that the European Medicines Agency (EMA) has granted access to the Agency's priority medicine program (PRIME) to its Sepofarsen therapy (QR-110), designed for the treatment of Leber congenital amaurosis (LCA10), a childhood blinding disorder, caused by the c.2991+1655A>G (p.Cys998 *) mutation in the CEP290 gene. The EMA PRIME program...

read more

DBGen presents a research optimizing the genetic diagnosis of color vision deficiency

DBGen is committed to the quality of genetic diagnosis and its major goal since the beginning of the company is to remain at the forefront of innovation, prioritize resolution of difficult cases, and optimize methodologies that increase the diagnostic yield of inherited ocular diseases. These objectives are clearly attainable due to the high expertise in the field of genetic diagnosis...

read more

Macular Week: Recent advances in pharmacotherapy for Stargardt disease

25/06/19 - Research, Patients, Stargardt,

Macular Week is all about sensitizing and informing patients, associations, professionals and society of latest achievements on macular degenerative pathologies. In this publication, we will focus on the news on orphan drugs that are currently in the clinical or preclinical phase for the treatment of Stargardt disease. Stargardt disease, the most common inherited macular dystrophy, is characterized by the progressive...

read more
1 2 3 6
Copyright © 2019. All Rights Reserved -